Featuring perspectives from Dr Erika Hamilton, Dr Jane Lowe Meisel, Dr Joyce O’Shaughnessy and Dr Seth Wander, including the following topics:

• Introduction (0:00)
• Current and Future Management of HR-Positive, HER2-Negative Localized Breast Cancer — Dr Meisel(2:40)
• Optimizing First-Line Therapy for Patients with HR-Positive Metastatic Breast Cancer (mBC) — Dr Hamilton (36:57)
• Current and Future Role of Oral Selective Estrogen Receptor Degraders for Progressive HR-Positive mBC — Dr Wander (58:18)
• Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive mBC — Dr O'Shaughnessy (1:18:00)

CME information and select publications

Featuring perspectives from Dr Kevin Punie and Dr Tiffany A Traina, including the following topics:

• Introduction: Where We Are; Where We’re Heading (0:00)
• First-Line Treatment of BRCA Wild-Type Disease (9:14)
• First-Line Treatment of BRCA-Mutant Disease (38:48)
• Novel Approaches (47:49)

CME information and select publications

Featuring perspectives from Dr Erika Hamilton and Dr Shanu Modi, including the following topics:

• Introduction (0:00)
• Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer — Dr Modi (0:58)
• Contemporary Management of HER2-Positive Metastatic Breast Cancer — Dr Hamilton (25:51)

CME information and select publications